SHIFT Newsroom · GLOBAL
GLP-1 medicines and skin conditions: what the review explores
This narrative review discusses potential dermatological uses and remaining evidence gaps. Proposed applications are not proof of an established treatment benefit or a new licensed indication.
What the source says
This narrative review discusses potential dermatological uses and remaining evidence gaps. Proposed applications are not proof of an established treatment benefit or a new licensed indication.
Evidence and limits
The review discusses inflammatory skin conditions alongside obesity and metabolic disease, drawing on several types of evidence. It proposes a framework for future care; that proposal does not establish a new routine indication.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
Weight-management medicines should not be presented here as established treatments for skin disease. Take questions about a skin condition to the relevant clinician.
Known facts
- This narrative review discusses potential dermatological uses and remaining evidence gaps.